OTCMKTS:MEOBF Mesoblast (MEOBF) Stock Price, News & Analysis $1.43 0.00 (0.00%) As of 05/23/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock About Mesoblast Stock (OTCMKTS:MEOBF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mesoblast alerts:Sign Up Key Stats Today's Range$1.43▼$1.4350-Day Range$1.05▼$1.5052-Week Range$0.56▼$5.34VolumeN/AAverage Volume169,320 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More… Mesoblast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreMEOBF MarketRank™: Mesoblast scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mesoblast. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Mesoblast's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 123804.3, which indicates bearish sentiment.Change versus previous monthShort interest in Mesoblast has recently decreased by 0.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 123804.3, which indicates bearish sentiment.Change versus previous monthShort interest in Mesoblast has recently decreased by 0.85%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 27.35% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Receive MEOBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MEOBF Stock News HeadlinesMesoblast Secures Seven-Year FDA Orphan-Drug Exclusivity for Ryoncil®May 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedMay 13, 2025 | tipranks.comMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMissed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.May 24, 2025 | Behind the Markets (Ad)JPMorgan Ceases Substantial Holding in Mesoblast LimitedMay 8, 2025 | tipranks.comState Street Corporation Ceases Substantial Holding in Mesoblast LimitedMay 7, 2025 | tipranks.comMesoblast Expands U.S. Market with Ryoncil® Launch and Advances Other TherapiesApril 30, 2025 | tipranks.comMesoblast Limited Appoints New Director Lyn CobleyApril 28, 2025 | tipranks.comMesoblast Limited Announces Director’s Interest ChangeApril 23, 2025 | tipranks.comSee More Headlines MEOBF Stock Analysis - Frequently Asked Questions How have MEOBF shares performed this year? Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MEOBF stock has decreased by 35.1% and is now trading at $1.4274. View the best growth stocks for 2025 here. How do I buy shares of Mesoblast? Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/24/2025Next Earnings (Estimated)7/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MEOBF CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:MEOBF) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.